Epinex Test Could Transform Diabetes Care
IRVINE, Calif., March 26 /PRNewswire/ -- On March 18th, Frost & Sullivan presented Epinex with its prestigious global diabetes research award. The award was given in recognition of Epinex's innovative G1A(TM) Rapid Diabetes Monitoring Index Test, which uses glycated albumin to measure the damage caused by excess sugar in the body.
Diabetes is one of the biggest contributors to our healthcare crisis. Preventive care programs could significantly reduce the human and financial costs of diabetes. The impending shift to preventive care has opened the door for a small company like Epinex to make a big difference in the healthcare system and in the lives of diabetics. The Epinex G1A(TM) test has the potential to transform diabetes care by introducing a more effective monthly diabetes management paradigm.
Preventive care will drive healthcare policy in the future. In his effort to revamp our crippled healthcare system, President Obama has called for investing unprecedented resources into preventive health care. President Obama once again targeted healthcare reform as the best way to "bend the curve on...deficit projections" at his news conference on Tuesday.
"The current economic crisis has leveled the playing field between Main Street and Wall Street," declared Epinex CEO Asad Zaidi during his acceptance speech. "As a Main Street biotech company, this award validates our work and will motivate us to...bring paradigm shifting disruptive technology into the marketplace. This award gives us the energy and momentum to break through the resistance of established medical practices."
The Obama Administration has called for "tough choices" in cutting medical costs. Healthcare companies are challenged to respond by investing in innovative products that will meet future healthcare needs. Epinex's award-winning research has been recognized as a step forward in meeting that challenge.
About Epinex Diagnostics, Inc.
Epinex Diagnostics is a privately owned medical device company with a vision to help alleviate the current healthcare crisis through the development of innovative point-of-care technologies using rapid diagnostic tests. Please find further information about the company and the G1A(TM) test at www.epinex.com.
Contact: Jacqueline Morales Public Relations Epinex Diagnostics, Inc. Phone 949-660-7770, ext. 106 email@example.com
|SOURCE Epinex Diagnostics, Inc.|
Copyright©2009 PR Newswire.
All rights reserved